{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:23:43Z","timestamp":1790713423617,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.psc.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T18:06:00Z","timestamp":1427306760000},"page":"309-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research"],"prefix":"10.1016","volume":"38","author":[{"given":"Kalyani","family":"Kansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2015.02.002_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/CPJ.0b013e31826b2ae8","article-title":"Diagnosis and treatment of rapidly progressive dementias","volume":"2","author":"Paterson","year":"2012","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.psc.2015.02.002_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/NRL.0b013e31820ba5e3","article-title":"The evaluation of rapidly progressive dementia","volume":"17","author":"Rosenbloom","year":"2011","journal-title":"Neurologist"},{"key":"10.1016\/j.psc.2015.02.002_bib3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(12)60069-5","article-title":"Adult primary central nervous system vasculitis","volume":"380","author":"Salvarani","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2015.02.002_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1756285609347123","article-title":"Diagnosis and treatment of cerebral vasculitis","volume":"3","author":"Berlit","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.psc.2015.02.002_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02934715","article-title":"Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or Hashimoto\u2019s encephalopathy)","volume":"1","author":"Tamagno","year":"2006","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.psc.2015.02.002_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ana.21430","article-title":"Rapidly progressive dementia","volume":"64","author":"Geschwind","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11910-009-0053-2","article-title":"Immunologically mediated dementias","volume":"9","author":"Rosenbloom","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.psc.2015.02.002_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(99)80135-1","article-title":"Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests","volume":"99","author":"West","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.psc.2015.02.002_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis: diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.psc.2015.02.002_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/NRL.0b013e31813e34a5","article-title":"Limbic encephalitis and variants: classification, diagnosis and treatment","volume":"13","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.psc.2015.02.002_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","article-title":"Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody","volume":"62","author":"Thieben","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.psc.2015.02.002_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.humpath.2005.01.014","article-title":"Lymphomatosis cerebri as a cause of white matter dementia","volume":"36","author":"Rollins","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.psc.2015.02.002_bib15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.21611","article-title":"Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis","volume":"65","author":"Yao","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-444-53488-0.00004-3","article-title":"Clinical approach to the syndromes of viral encephalitis, myelitis, and meningitis","volume":"123","author":"Cho","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.clineuro.2008.04.014","article-title":"Isolated central nervous system Whipple's disease causing reversible frontotemporal-like dementia","volume":"110","author":"Benito-Le\u00f3n","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.psc.2015.02.002_bib20","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.psc.2015.02.002_bib21","series-title":"WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.psc.2015.02.002_bib22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.0b013e31826d5fc3","article-title":"Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Muayqil","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/WNL.0b013e318263565f","article-title":"A\u00a0comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease","volume":"79","author":"Hamlin","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","article-title":"Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry","volume":"71","author":"Skillb\u00e4ck","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/01.wnl.0000230159.67128.00","article-title":"CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease","volume":"67","author":"Sanchez-Juan","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4161\/pri.26416","article-title":"PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2","volume":"7","author":"Llorens","year":"2013","journal-title":"Prion"},{"key":"10.1016\/j.psc.2015.02.002_bib27","doi-asserted-by":"crossref","first-page":"e36159","DOI":"10.1371\/journal.pone.0036159","article-title":"Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease","volume":"7","author":"Torres","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.psc.2015.02.002_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3233\/JAD-2009-1110","article-title":"Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders","volume":"17","author":"Meyne","year":"2009","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2015.02.002_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","article-title":"Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion","volume":"17","author":"Atarashi","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.psc.2015.02.002_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.23589","article-title":"Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease","volume":"72","author":"McGuire","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib31","doi-asserted-by":"crossref","first-page":"e54915","DOI":"10.1371\/journal.pone.0054915","article-title":"Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay","volume":"8","author":"Sano","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.psc.2015.02.002_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2014.4068","article-title":"Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease","author":"Dorey","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.69.1.5","article-title":"Inborn errors of metabolism as a cause of neurological disease in adults: an approach to investigation","volume":"69","author":"Gray","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.psc.2015.02.002_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1542\/peds.2007-0391","article-title":"Mitochondrial disease: a practical approach for primary care physicians","volume":"120","author":"Haas","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.psc.2015.02.002_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00401-010-0721-y","article-title":"Brain biopsy in dementia: clinical indications and diagnostic approach","volume":"120","author":"Schott","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3171\/jns.2007.106.1.72","article-title":"The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia","volume":"106","author":"Josephson","year":"2007","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.psc.2015.02.002_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3201\/eid1005.030711","article-title":"Rapidly progressive dementia due to Mycobacterium neoaurum meningoencephalitis","volume":"10","author":"Heckman","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.psc.2015.02.002_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ncpneuro0804","article-title":"A\u00a0case of enteroviral meningoencephalitis presenting as rapidly progressive dementia","volume":"4","author":"Valcour","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2018s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature12481","article-title":"Self-propagation of pathogenic protein aggregates in neurodegenerative diseases","volume":"501","author":"Jucker","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.psc.2015.02.002_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"20","author":"Guo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.psc.2015.02.002_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.psc.2015.02.002_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00401-013-1238-y","article-title":"Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD)","volume":"127","author":"Brettschneider","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ana.23937","article-title":"Stages of pTDP-43 pathology in amyotrophic lateral sclerosis","volume":"74","author":"Brettschneider","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaneurol.2013.1933","article-title":"Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone","volume":"70","author":"Irwin","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jalz.2010.03.008","article-title":"Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects","volume":"6","author":"Trojanowski","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2015.02.002_bib49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib50","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/jnnp-2012-303144","article-title":"Therapeutic strategies for tau mediated neurodegeneration","volume":"84","author":"Yoshiyama","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.psc.2015.02.002_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","article-title":"Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke","volume":"2","author":"Hesse","year":"2000","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2015.02.002_bib52","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","article-title":"Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury","volume":"67","author":"Ost","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib53","first-page":"620","article-title":"Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections","volume":"260","author":"Krut","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0896-6273(94)90264-X","article-title":"Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau","volume":"13","author":"Matsuo","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.psc.2015.02.002_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.22015","article-title":"Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology","volume":"68","author":"Hamilton","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib56","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in\u00a0vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2015.02.002_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2015.02.002_bib59","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/archneurol.2012.26","article-title":"Comparison of cerebrospinal fluid levels of tau and A\u03b2 1-42 in Alzheimer disease and frontotemporal degeneration using 2\u00a0analytical platforms","volume":"69","author":"Irwin","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2015.02.002_bib61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-011-0808-0","article-title":"Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI","volume":"121","author":"Shaw","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2018s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2015.02.002_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-2012-110029","article-title":"Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease","volume":"33","author":"Le Bastard","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2015.02.002_bib64","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3233\/JAD-2012-120019","article-title":"Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment","volume":"30","author":"Mattsson","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2015.02.002_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","article-title":"Longitudinal change in CSF Tau and A\u03b2 biomarkers for up to 48 months in ADNI","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson Progression Marker Initiative (PPMI)","volume":"95","author":"Parkinson Progression Marker Initiative","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.psc.2015.02.002_bib67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00401-012-0983-7","article-title":"CSF biomarkers cutoffs: the importance of coincident neuropathological diseases","volume":"124","author":"Toledo","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib68","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/01.wnl.0000311445.21321.fc","article-title":"CSF biomarkers in frontotemporal lobar degeneration with known pathology","volume":"70","author":"Bian","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update","volume":"119","author":"Mackenzie","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib70","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","article-title":"Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP","volume":"81","author":"Hu","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib71","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamaneurol.2013.6064","article-title":"Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis","volume":"71","author":"Grossman","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib72","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/archneur.65.11.1481","article-title":"TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"65","author":"Steinacker","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib73","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1471-4159.2012.07911.x","article-title":"Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies","volume":"123","author":"Luk","year":"2012","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.psc.2015.02.002_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neurobiolaging.2007.05.009","article-title":"Pattern of Tau forms in CSF is altered in progressive supranuclear palsy","volume":"30","author":"Borroni","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.psc.2015.02.002_bib75","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.psc.2015.02.002_bib76","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib77","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease","volume":"24","author":"Compta","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.psc.2015.02.002_bib78","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/mds.23287","article-title":"CSF A\u03b2(42) and tau in Parkinson's disease with cognitive impairment","volume":"25","author":"Montine","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.psc.2015.02.002_bib79","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib81","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psc.2015.02.002_bib82","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer's disease","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.psc.2015.02.002_bib83","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib84","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e318200d78d","article-title":"Novel CSF biomarkers for frontotemporal lobar degenerations","volume":"75","author":"Hu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2015.02.002_bib85","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","article-title":"Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment","volume":"119","author":"Hu","year":"2010","journal-title":"Acta Neuropathol"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X1500026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X1500026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T12:01:31Z","timestamp":1566475291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X1500026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0193953X1500026X"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2015.02.002","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}